Molecular assays are instrumental in the clinical management of viral hepatitis. During the past years, a wide variety of molecular assays have been developed and implemented. This considerably improved the understanding of the natural history and pathogenesis of Hepatitis B virus (HBV), Hepatitis C virus (HCV) or Hepatitis delta virus (HDV) hepatitis, but also caused uncertainties in the selection of the most appropriate assays for clinical requirements. Indeed, a rational choice and application of these assays requires adequate knowledge of the performance of the single test. Moreover, the choice of the most accurate assay for patients' needs and physicians' objectives, needs to be oriented to specific contexts, such as diagnosis, management or treatment. In the past, a hurdle in the routine use of assays for hepatitis viruses nucleic acid quantification was represented by the availability of only "home brew" methods which lacked standardization. Major improvement in addressing the use of molecular assays for viral hepatitis has been derived from recent standardization procedures that allowed a comparison between different tests after results were given as International Units. In addition, it should be reminded that, before getting into the market, molecular assays should be approved by European regulation authorities and validated using internationally recognized standards. A subsequent clinical validation should address the diagnostic accuracy of the assay. These proceedings have the aim of identifying which molecular tests, among those currently available, meet clinical requirements for each specific application.

Mangia, A., Antonucci, F., Brunetto, M., Capobianchi, M., Fagiuoli, S., Guido, M., et al. (2008). The use of molecular assays in the management of viral hepatitis. DIGESTIVE AND LIVER DISEASE, 40(6), 395-404 [10.1016/j.dld.2007.12.016].

The use of molecular assays in the management of viral hepatitis

Fagiuoli S;Puoti M;
2008

Abstract

Molecular assays are instrumental in the clinical management of viral hepatitis. During the past years, a wide variety of molecular assays have been developed and implemented. This considerably improved the understanding of the natural history and pathogenesis of Hepatitis B virus (HBV), Hepatitis C virus (HCV) or Hepatitis delta virus (HDV) hepatitis, but also caused uncertainties in the selection of the most appropriate assays for clinical requirements. Indeed, a rational choice and application of these assays requires adequate knowledge of the performance of the single test. Moreover, the choice of the most accurate assay for patients' needs and physicians' objectives, needs to be oriented to specific contexts, such as diagnosis, management or treatment. In the past, a hurdle in the routine use of assays for hepatitis viruses nucleic acid quantification was represented by the availability of only "home brew" methods which lacked standardization. Major improvement in addressing the use of molecular assays for viral hepatitis has been derived from recent standardization procedures that allowed a comparison between different tests after results were given as International Units. In addition, it should be reminded that, before getting into the market, molecular assays should be approved by European regulation authorities and validated using internationally recognized standards. A subsequent clinical validation should address the diagnostic accuracy of the assay. These proceedings have the aim of identifying which molecular tests, among those currently available, meet clinical requirements for each specific application.
Articolo in rivista - Articolo scientifico
Genotypes; HDV RNA; Qualitative HCV RNA; Quantitative HBV DNA; Quantitative HCV RNA; Viral hepatitis;
English
395
404
10
Mangia, A., Antonucci, F., Brunetto, M., Capobianchi, M., Fagiuoli, S., Guido, M., et al. (2008). The use of molecular assays in the management of viral hepatitis. DIGESTIVE AND LIVER DISEASE, 40(6), 395-404 [10.1016/j.dld.2007.12.016].
Mangia, A; Antonucci, F; Brunetto, M; Capobianchi, M; Fagiuoli, S; Guido, M; Farci, P; Lampertico, P; Marzano, A; Niro, G; Pisani, G; Prati, D; Puoti, M; Raimondo, G; Santantonio, T; Smedile, A; Lauria, F
File in questo prodotto:
File Dimensione Formato  
mangia DLD.pdf

Solo gestori archivio

Dimensione 145.82 kB
Formato Adobe PDF
145.82 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/354017
Citazioni
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 14
Social impact